Vivaldi Biosciences and BlueSky Vaccines form agreement on high growth influenza strain tech
FORT COLLINS and VIENNA, Austria -- Vivaldi Biosciences Inc ., a clinical-stage company developing the deltaFLU universal influenza vaccine, announced it signed a technology co-ownership... Read More
Wednesday October 16, 2019
InDevR licenses FDA influenza antibodies for VaxArray potency platform
BOULDER -- InDevR , a Boulder-based progressive analytical technology and life science instrumentation company, today announced it has entered into an agreement to license monoclonal antibodies... Read More
Tuesday January 17, 2017
PharmaJet gets first FDA approval to use needle-free injection technology for flu shots
GOLDEN - PharmaJet , developer of a needle-free injection technology for administering medications and vaccines, has received approval from the FDA for its Stratis 0.5mL Needle-Free Jet... Read More
Tuesday August 19, 2014
Vivaldi Biosciences signs agreement with NIAID to develop pandemic flu drug
FORT COLLINS - Vivaldi Biosciences Inc. , a clinical-stage biotech company developing live attenuated influenza vaccines (LAIVs) against seasonal and pandemic flu, announced it has signed a... Read More
Wednesday January 22, 2014
IN Sponsors
Browse
Entrepreneurial by Nature
